about
Peptidylarginine Deiminases as Drug Targets in Neonatal Hypoxic-Ischemic EncephalopathyAdaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous systemNuclear receptor unfulfilled regulates axonal guidance and cell identity of Drosophila mushroom body neurons.Mitochondrial disorders and the eye.Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protectionExtension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse.PPAR-alpha and PPAR-beta expression changes in the hippocampus of rats undergoing global cerebral ischemia/reperfusion due to PPAR-gamma statusPeptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonatesPPARγ agonists promote oligodendrocyte differentiation of neural stem cells by modulating stemness and differentiation genesHyperbaric oxygen preconditioning attenuates hemorrhagic transformation through increasing PPARγ in hyperglycemic MCAO rats.Systems pharmacology dissection of multi-scale mechanisms of action for herbal medicines in stroke treatment and prevention.Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.25-Hydroxycholesterol-3-sulfate attenuates inflammatory response via PPARγ signaling in human THP-1 macrophages.KLF11 mediates PPARγ cerebrovascular protection in ischaemic stroke.Rapid pain modulation with nuclear receptor ligands.Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.Potential Therapeutic Targets for PPARgamma after Spinal Cord Injury.PPAR Regulation of Inflammatory Signaling in CNS Diseases.Clovamide and rosmarinic acid induce neuroprotective effects in in vitro models of neuronal death.Potential molecular targets for translational stroke research.Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.New insights into huperzine A for the treatment of Alzheimer's disease.T33, a novel peroxisome proliferator-activated receptor γ/α agonist, exerts neuroprotective action via its anti-inflammatory activitiesMicroglial activation in stroke: therapeutic targets.Therapeutic Potential of PPARγ Activation in Stroke.Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders.Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.15d-PGJ2 Reduced Microglia Activation and Alleviated Neurological Deficit of Ischemic Reperfusion in Diabetic Rat Model.Polyunsaturated fatty acids and endocannabinoids in health and disease.Stroke status evoked adhesion molecule genetic alterations in astrocytes isolated from stroke-prone spontaneously hypertensive rats and the apigenin inhibition of their expressionRescue of neurons from ischemic injury by peroxisome proliferator-activated receptor-gamma requires a novel essential cofactor LMO4Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model.15-Deoxy-∆12,14-PGJ 2, by activating peroxisome proliferator-activated receptor-gamma, suppresses p22phox transcription to protect brain endothelial cells against hypoxia-induced apoptosis.Fatty Acids, Antioxidants and Physical Activity in Brain Aging.Oral administration of a novel lipophilic PPARδ agonist is not neuroprotective after rodent cerebral ischemia.Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.Recombinant Netrin-1 binding UNC5B receptor attenuates neuroinflammation and brain injury via PPARγ/NFκB signaling pathway after subarachnoid hemorrhage in rats.Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation.Modulation of the Nitrergic Pathway via Activation of PPAR-γ Contributes to the Neuroprotective Effect of Pioglitazone Against Streptozotocin-Induced Memory Dysfunction.
P2860
Q26768557-7A0A16F8-E014-4013-A77C-ABDC59514CD3Q28389419-C391F07B-D512-46E5-806D-EC3849B2335CQ33520248-A26EE2F6-EF71-423A-B0C3-0C69EB4DDB8CQ33702120-DCEB78AD-C16A-451B-997D-CDE51E27E907Q34088803-014244CB-D1D3-40C6-96B9-49EAB56BAF41Q34126249-E1C04841-C898-4A61-B2A5-8BF675AD514EQ34170824-51C32A34-B1B6-47A1-852A-16AD5C0E6649Q34203838-3E1FA728-3680-4976-AE9B-C2169E3C20FDQ34290066-686496C0-D5FB-45A6-8D5F-CC7C3E24CF82Q34491511-CBB221BF-56D3-4226-9453-544A8573E11CQ35137691-BF54C7FF-B087-4F16-972F-B93C473C6731Q35219375-8FE56A2F-1BF5-48BD-A787-D1777FDA9B6BQ35696867-D568F404-2E33-40EB-97AA-2DCC6F19C847Q35900607-0FDA4E49-1903-4965-8091-B89A79476AE3Q36732823-88AB96E5-938A-4ED2-B71C-E65CA4FAAAFEQ36964412-27FFBB91-4232-45A6-8B81-0A2E3AADC6EDQ36992256-D24CEBF1-130F-4A55-BE35-50A22315DE10Q37134018-F967E41C-696F-46E6-8025-E2706EFB5CE7Q37231755-53C6A63B-D41E-4FE2-996A-3A9802975AE4Q37332668-ADAA2549-83C3-4CC7-A29B-8816565CFD33Q37344146-BC5D3832-9D5E-4C38-8991-C032F8A7B2A6Q37376937-27F44C7E-7950-480B-B362-9575B6EC405DQ37729474-66D173A5-E375-44CD-8972-143AD1909DC6Q37729802-15D9B91F-5AFE-424E-BA98-51CAFD06D348Q37794381-0FF36377-EC68-4066-A0A7-7742E3AEFD2DQ37930425-24D9AF94-F4CE-453C-825F-63B83926F54EQ37995569-8210F9F3-C43B-4D1F-BD99-3D6361260467Q38066606-405B47E0-BF45-42F3-BC71-5DFD30C14C25Q38912231-50C18A38-76E9-44D8-B3D9-DDDF60C57BA3Q39421016-FA548BAE-4BE1-4D1A-9ADE-14E33F7C0C72Q41901366-94A171C1-B57E-41C6-83F8-5A571AD6A6C3Q42410542-48C75486-BE93-48CF-B7B6-8B5084250C15Q42710539-786D607D-2EB0-4514-91C7-91011705E0AFQ46957674-251E8A4B-657F-4E15-9009-7E5CFC445357Q47156198-4659A62B-97C5-4729-A521-E26542B0E392Q47564690-2DA22257-9EB5-43FD-BFDD-8F89AC521E86Q47739408-E260B3C8-92BC-4A15-84C3-CB4FFFCE3356Q47786905-6EBF1CCF-1AFE-46B3-87C6-BDCF40A01C5BQ48034616-CC48283A-3E98-4928-A7D8-8D64C69B3180Q50742628-6EB2002D-CC7D-4692-A4BA-DCA5FCE2AC38
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
PPAR-gamma: therapeutic target for ischemic stroke.
@en
type
label
PPAR-gamma: therapeutic target for ischemic stroke.
@en
prefLabel
PPAR-gamma: therapeutic target for ischemic stroke.
@en
P2093
P1476
PPAR-gamma: therapeutic target for ischemic stroke.
@en
P2093
Juraj Culman
Peter Gohlke
Thomas Herdegen
P304
P356
10.1016/J.TIPS.2007.03.004
P577
2007-04-09T00:00:00Z